Updates
** Shares of drug developer Summit Therapeutics SMMT.O fall 12.6% to $19.33
** Company reports fourth-quarter net loss of $61.1 million, vs analysts' estimate of a loss of $60.54 million, as per data compiled by LSEG
** Brokerage Truist Securities analysts say: "from what we understand with our buyside discussions is that there were some expectations for deal announcements, perhaps with more economic scope than what was disclosed between SMMT & Pfizer"
** Brokerage added: "We think changes to SMMT's participation in investor conferences may not be a good indicator of potential deal announcements"
** SMMT says it is collaborating with Pfizer PFE.N to study its experimental drug ivonescimab in combination with several of Pfizer's targeted cancer therapies, called antibody drug conjugates (ADCs), across different types of tumors
** Stock has risen 5x in the last 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.